Macrocyclic peptides active against the hepatitis C virus
申请人:Boehringer Ingelheim (Canada) Ltd
公开号:US06608027B1
公开(公告)日:2003-08-19
The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus.
wherein W, R21, R22, R3, R4, D and A are as defined herein, or a pharmaceutically acceptable salts or ester thereof.